Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 2/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.47 |
| ▸ | P2RX2 | Q9UBL9 | 2/20 | 0.47 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.44 |
| ▸ | AHCY | P23526 | 3/20 | 0.44 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.43 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.43 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | P2RX6 | O15547 | 1/20 | 0.42 |
| ▸ | P2RX1 | P51575 | 1/20 | 0.42 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.42 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.42 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.42 |
| ▸ | GSK3A | P49840 | 1/20 | 0.42 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5558228 | 0.87 | P2RX3 (0.51) | P2RX3P2RX4P2RX2STING1AHCY | |
| SCHEMBL12851723 | 0.86 | ALDH1A1 (0.44) | P2RX3P2RX4P2RX2P2RY11 | |
| SCHEMBL5557886 | 0.85 | P2RX3 (0.48) | P2RX3P2RX4P2RX2STING1AHCY | |
| SCHEMBL18573966 | 0.80 | P2RX3 (0.53) | P2RX3P2RX4P2RX2STING1AHCY | |
| SCHEMBL16473389 | 0.80 | PRMT6 (0.53) | — | |
| SCHEMBL17445611 | 0.80 | PRMT6 (0.53) | — | |
| SCHEMBL10191583 | 0.80 | PRMT6 (0.53) | — | |
| SCHEMBL5553654 | 0.77 | P2RX3 (0.41) | P2RX3P2RX4P2RX2STING1AHCY | |
| SCHEMBL12851609 | 0.77 | PRMT6 (0.48) | — | |
| SCHEMBL18073287 | 0.77 | HSP90B1 (0.46) | AHCYHSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8278425-B2 | N-substituted-aminomethylene bridged bicyclic nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-10-02 | — | — | US | disclosed |
| US-20100249211-A1 | N-Substituted-Aminomethylene Bridged Bicyclic Nucleic Acid Analogs | IONIS PHARMACEUTICALS, INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249211-A1 | N-Substituted-Aminomethylene Bridged Bicyclic Nucleic Acid Analogs | NSUN2, RNMT, NSUN3 | P2RX3 4123/4885P2RX4 4176/4885P2RX2 4226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.